Choosing a real-world evidence platform: what actually matters

Executive summary

A real-world evidence platform should be evaluated by its ability to generate evidence that supports clinical, regulatory, and commercial decisions.

• Buyers should evaluate whether a real-world evidence (RWE) platform can turn multi-modal data into decision-ready evidence.
• Teams should assess evidence in context and consider analytical validity, clinical relevance, reproducibility, and intended use.
• Buyers should evaluate five areas: data integration, cohort definition, outcome analysis, validation and reproducibility, and governance for secure collaboration.
• These capabilities support clinical development, HEOR, post-market research, oncology, rare disease, and precision medicine use cases.
• BC Catalyst and BC Mosaic address these requirements by supporting evidence-generation workflows and secure, governed data access.

Why a real-world evidence platform can fall short

A real-world evidence platforms helps life sciences teams combine, analyze, and validate real-world data so findings can support clinical, regulatory, market access, and commercial decisions. Choosing the right RWE platform matters because evidence quality depends on much more than analytics alone.

Many real-world evidence platforms are evaluated based on their analytical capabilities. Analytics, however, are rarely the limiting factor.

Most platforms can generate outputs. The harder test is whether teams can trust, reuse, and apply those outputs across studies, functions, and regulatory contexts. Fragmented data, unclear cohort definitions, inconsistent methods, and poor reproducibility can undermine validity. Findings that appear promising in one analysis may not support later studies or decisions.

Regulatory agencies and scientific literature consistently emphasize the need to generate evidence in context. Teams must consider analytical validity, clinical relevance, reproducibility, and intended use when evaluating findings. These principles apply across clinical development, HEOR, post-market research, precision medicine, and other evidence-generation programs.

Teams encounter these requirements across RWE use cases, from clinical development and HEOR to post-market studies. Advanced applications such as biomarker research may make these challenges more visible, but the core platform requirements remain the same.

A better way to compare real-world evidence platforms

Many real-world evidence platforms emphasize analytics features, scale, or AI capabilities. These claims alone do not show whether a platform can generate evidence that supports real decisions.

A better comparison focuses on the work teams actually need to do and the points where studies often break down. Teams must combine heterogeneous data, define patient populations transparently, link findings to outcomes, validate results, and ensure they can reproduce and reuse their work across studies.

These challenges appear across real-world evidence studies, including clinical development, HEOR, and post-market research.

The most effective way to evaluate a real-world evidence platform is to assess whether it supports five core capabilities:

1. Can the RWE platform combine the right data for studies?

Real-world evidence generation rarely relies on a single dataset. Most studies require teams to combine clinical data, treatment history, outcomes, genomics, imaging, and other real-world data sources to build a complete view of patients and their clinical context.

Data integration is often where studies break down. Data sits across multiple systems, institutions, and formats that can be difficult to reconcile. As a result, teams may rely on incomplete or inconsistent inputs. Those limitations can weaken findings and reduce confidence in decision-making.

Buyers should evaluate whether a platform can bring different types of data together in a form that supports analysis. The platform should align datasets, manage differences in data models, and preserve clinical context, including the timing of key events.

Without integrated, context-rich data, teams cannot generate strong evidence.

2. Can the platform support transparent cohort definition?

Cohort definition is one of the most important steps in real-world evidence generation. It is also one of the most frequently overlooked. Small changes to inclusion criteria, endpoints, or data quality thresholds can significantly affect study results.

Teams often define slightly different cohorts when addressing the same research question. As a result, studies may produce conflicting findings that are difficult to reconcile. Opaque queries and fragmented workflows create additional challenges. They make it harder to understand how teams constructed populations and to repeat analyses consistently. This reduces confidence in the findings, especially in regulatory and decision-making settings.

Buyers should look for platforms that support transparent, traceable, and reusable cohort definition. The platform should provide clear logic, version control, and consistent methods across studies. These capabilities become especially important in complex areas such as oncology and rare disease. However, the requirement applies across all real-world evidence research. If teams cannot clearly define and reproduce cohorts, they cannot fully trust the resulting evidence.

3. Can the platform connect analyses to outcomes that matter?

Running analyses is not the same as generating useful evidence. What matters is whether a platform can connect patient characteristics, treatments, and interventions to clinically meaningful outcomes and endpoints.

Many studies lose momentum at this stage. Platforms may identify signals or associations, but teams often struggle to connect those findings to meaningful outcomes. Without that connection, decision-makers cannot easily interpret or act on the results. Findings may appear promising yet still fall short of the endpoints needed to support clinical, regulatory, or commercial decisions. This creates a gap between analysis and action.

Buyers should look for platforms that support outcome analysis tied to decision-relevant endpoints. Teams should be able to define outcomes, track them over time, and evaluate how treatments or patient characteristics affect them. This requirement extends across real-world evidence studies. To support decisions, findings must connect to outcomes that matter in clinical, regulatory, and commercial settings.

4. Can the platform support validation and reproducibility?

Generating results is not enough. Teams must be able to trace, reproduce, and defend real-world evidence.

The challenges often emerge when teams cannot clearly see the methods, assumptions, or data transformations behind an analysis. Without that visibility, they struggle to validate findings across datasets or reuse analyses in future studies. In regulated environments, these limitations can reduce confidence in the evidence. Decision-makers are unlikely to rely on results they cannot reproduce, audit, or independently verify.

Buyers should look for platforms that make validation and reproducibility part of the workflow. The platform should provide traceability, auditability, and the ability to test and reuse analyses across studies and teams. Without reproducibility, even strong findings may have limited value.

5. Can the platform operate within governance and collaboration constraints?

RWE generation takes place within data access controls, privacy requirements, and institutional governance frameworks. These constraints often determine what research teams can realistically accomplish.

Governance challenges can limit study scope and delay progress. Organizations may restrict data access, prevent data movement, or limit collaboration across sites. These barriers become even more significant in multi-site and cross-border research. As a result, teams may narrow their studies, delay analyses, or abandon important research questions.

Buyers should evaluate whether a platform enables analysis within these constraints. The platform should provide controlled access, secure workspaces, and collaboration models that support compliant research across institutions. In many cases, teams need to bring analysis to the data rather than move data into a central environment. Platforms that cannot support this approach may restrict the research organizations can perform.

What to compare in a real-world evidence platform

Buyers should focus on a small set of practical questions when evaluating a real-world evidence platform. These questions reveal whether the platform can generate evidence that stands up in real-world settings.

These are the areas where many real-world evidence efforts lose value. Platforms that do not address these challenges make studies harder to replicate. They also make findings more difficult to validate across datasets and reduce their usefulness for clinical, regulatory, and commercial decisions.

Many platform strategies fall short because they prioritize infrastructure, features, or standalone analytics. Teams often gain more value from capabilities that help them combine, reuse, and apply data across studies and partners. Without those capabilities, researchers must rebuild datasets, redefine cohorts, and rerun analyses. This slows research programs and limits the impact of real-world evidence.

This approach provides a stronger basis for comparison than broad claims about AI, scale, or automation. It focuses on the conditions required to generate evidence that remains useful beyond a single analysis.

How a real-world evidence platform differs in practice

The differences between real-world evidence platforms become clear during real studies. Research teams need to combine data, define cohorts consistently, connect findings to meaningful outcomes, and reproduce results across datasets and teams. This is where platform limitations often become visible.

Some platforms make it difficult to repeat analyses consistently. Others struggle to connect findings to decision-relevant endpoints or support research across governance and collaboration constraints. These challenges can limit the value of otherwise promising analyses.

How BC Platforms delivers these capabilities in practice

Real-world evidence cannot be generated through a single system or workflow. Different research questions require different approaches to data access, integration, governance, and analysis.

Some questions can be answered using large aggregated datasets. Others require direct analysis of anonymized patient-level data within secure, governed environments. Both approaches help teams generate evidence that is clinically meaningful, reproducible, and useful in practice. They also support different research questions throughout the product lifecycle.

BC Catalyst: supporting analysis at scale

BC Catalyst supports analysis at scale through a single, intuitive, AI-powered web interface. It brings together real-world data, genomic and clinical data, and trial intelligence so teams can define cohorts, explore relevant signals, and analyze treatment patterns and outcomes across aggregated datasets. This makes it easier to generate hypotheses and produce population-level evidence when patient-level access is not required.

BC Mosaic: enabling secure analysis

BC Mosaic enables secure analysis in settings where organizations cannot move or centralize data. It is a trusted research environment (TRE) that provides governed access to anonymized patient-level data across institutions. Teams can validate findings, connect data to outcomes in context, and conduct studies within real-world governance and collaboration constraints. Additional tools and applications can support advanced analytics and compute-intensive research.

Combining both approaches for decision-ready evidence

Together, BC Catalyst and BC Mosaic reflect how teams generate evidence in practice. Researchers may explore questions at scale using aggregated datasets and then validate findings through patient-level analysis in secure research environments.

This approach helps teams generate evidence they can validate, reproduce, interpret in context, and apply to clinical development, precision medicine, and other decision-making activities.

Conclusion

A real-world evidence platform should help teams generate evidence that is trustworthy, validated, reproducible, and usable for clinical, regulatory, market access, and commercial decisions. It requires more than analytics features or access to data alone.

That requires more than analytics features or access to data. Teams need the ability to integrate and master data, define cohorts consistently, connect analyses to meaningful outcomes, reproduce results, and work within real-world governance constraints.

The platforms that stand out support the full evidence workflow, from data preparation and cohort design to validation, interpretation, and governed collaboration

References

Kim E et al. Enabling Real World Data to Accelerate the Development of Therapeutics (2023).